William J. Catalona

Q: What Schools Are Affiliated With William J. Catalona

William J. Catalona is affiliated with the following schools: Northwestern University, Queen's University at Kingston, Baylor College of Medicine, University of Cambridge, University of Pennsylvania

William J. Catalona's AcademicInfluence.com Rankings

William J. Catalona

Philosophy

#2950

World Rank

#4888

Historical Rank

Logic

#867

World Rank

#1428

Historical Rank

philosophy Degrees

Download Badge

Philosophy

William J. Catalona's Degrees

Doctorate Medicine University of Chicago

Why Is William J. Catalona Influential?

(Suggest an Edit or Addition)

(See a Problem?)

William J. Catalona's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. (1991) (2300)
Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. (1998) (1176)
REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. (2016) (1110)
High-throughput oncogene mutation profiling in human cancer (2007) (1041)
Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. (1993) (1017)
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24 (2007) (904)
Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. (2004) (823)
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes (2007) (765)
Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. (1999) (733)
Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. (1997) (712)
Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. (1992) (694)
Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. (1995) (683)
A common variant associated with prostate cancer in European and African populations (2006) (630)
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types (2009) (613)
Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. (1994) (564)
Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. (2004) (548)
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. (2004) (521)
5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. (1994) (517)
Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. (1995) (479)
Clinical use of prostate specific antigen in patients with prostate cancer. (1989) (472)
Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. (1994) (453)
Urothelial Tumors of the Urinary Tract (1992) (452)
A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. (2011) (437)
Expression profiling reveals hepsin overexpression in prostate cancer. (2001) (407)
Serial biopsy results in prostate cancer screening study. (2002) (387)
Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. (1990) (378)
Return of erections and urinary continence following nerve sparing radical retropubic prostatectomy. (1993) (368)
Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility (2009) (360)
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer (2008) (337)
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. (2000) (326)
Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. (2003) (321)
Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. (1994) (314)
Management of cancer of the prostate. (1994) (309)
Modified inguinal lymphadenectomy for carcinoma of the penis with preservation of saphenous veins: technique and preliminary results. (1988) (287)
Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. (1987) (271)
Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. (1998) (270)
A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. (2000) (265)
Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. (1994) (263)
A germline variant in the TP53 polyadenylation signal confers cancer susceptibility (2011) (261)
T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. (1993) (254)
Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. (1996) (253)
Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. (1994) (230)
The prostate health index selectively identifies clinically significant prostate cancer. (2015) (228)
Prostate cancer early detection. Clinical practice guidelines in oncology. (2010) (226)
Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. (1987) (222)
Lymphocyte reactivity in cancer patients: Correlation with tumor histology and clinical stage (1973) (220)
Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. (1993) (218)
Longitudinal screening for prostate cancer with prostate-specific antigen. (1996) (218)
NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. (2016) (215)
Interexaminer variability of digital rectal examination in detecting prostate cancer. (1995) (212)
Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. (1999) (208)
Prostate cancer early detection, Version 2.2016: Featured updates to the NCCN guidelines (2016) (206)
Circulating giant macrophages as a potential biomarker of solid tumors (2014) (202)
The nature of prostate cancer detected through prostate specific antigen based screening. (1994) (199)
A method for dinitrochlorobenzene contact sensitization. A clinicopathological study. (1972) (198)
Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. (1998) (198)
Pain and morbidity of transrectal ultrasound guided prostate biopsy: a prospective randomized trial of 6 versus 12 cores. (2000) (194)
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases (2002) (189)
Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. (1992) (187)
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG) (2012) (186)
A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer (2012) (185)
Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. (1994) (185)
Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. (2002) (184)
Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4. (2001) (180)
Neoadjuvant Docetaxel before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer (2005) (178)
Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. (2003) (173)
Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. (2006) (171)
The Prostate Health Index: a new test for the detection of prostate cancer (2014) (167)
Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with clinically localized prostate cancer. (1992) (167)
Impaired prostate tumorigenesis in Egr1-deficient mice (2001) (164)
Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. (2004) (161)
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. (2017) (160)
Genomewide scan for prostate cancer-aggressiveness loci. (2000) (158)
A genome screen of multiplex sibships with prostate cancer. (2000) (157)
Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. (2004) (157)
The early detection of prostate carcinoma with prostate specific antigen (1997) (156)
Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. (1994) (155)
Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. (1996) (155)
Genetic Correction of PSA Values Using Sequence Variants Associated with PSA Levels (2010) (154)
Staging errors in clinically localized prostatic cancer. (1982) (153)
NCCN clinical practice guidelines in oncology: prostate cancer early detection. (2010) (152)
Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. (2007) (149)
Tissue factor expression and angiogenesis in human prostate carcinoma. (2000) (149)
[-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. (2010) (149)
Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results. (1985) (147)
Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. (1999) (147)
Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. (1987) (141)
Nerve-sparing radical prostatectomy: extraprostatic tumor extension and preservation of erectile function. (1985) (141)
Unreliability of sentinel lymph node biopsy for staging penile carcinoma. (1980) (139)
Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. (1986) (138)
A prospective randomized comparison of three blood conservation strategies for radical prostatectomy. (1999) (138)
Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. (1999) (135)
Abnormalities of quantitative dinitrochlorobenzene sensitization in cancer patients: Correlation with tumor stage and histology (1973) (132)
Effect of ejaculation on serum total and free prostate-specific antigen concentrations. (1997) (131)
The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. (1999) (131)
Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. (1997) (130)
Characteristics of prostate cancer detected by digital rectal examination only. (2006) (130)
Contemporary results of anatomic radical prostatectomy (1999) (127)
Acute normovolemic hemodilution is a cost‐effective alternative to preoperative autologous blood donation by patients undergoing radical retropubic prostatectomy (1995) (120)
Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment. (1994) (119)
Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values. (1995) (118)
Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. (1995) (118)
Prostate-specific antigen in clinical practice. (2007) (117)
Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. (2005) (116)
Lowering PSA cutoffs to enhance detection of curable prostate cancer. (2000) (116)
Acute Normovolemic Hemodilution Can Replace Preoperative Autologous Blood Donation as a Standard of Care for Autologous Blood Procurement in Radical Prostatectomy (1997) (116)
Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. (1988) (115)
Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors. (1988) (114)
CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. (2003) (110)
Early complications of contemporary anatomical radical retropubic prostatectomy. (1994) (108)
MEK4 function, genistein treatment, and invasion of human prostate cancer cells. (2009) (108)
Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. (2006) (106)
γ Interferon induced by S. aureus protein A augments natural killing and ADCC (1981) (106)
Clinical utility of measurement free and total prostate‐specific antigen (PSA): A review (1996) (105)
Efficacy and cost-effectiveness of autologous blood predeposit in patients undergoing radical prostatectomy procedures. (1994) (103)
Nuclear Factor-κB-Mediated Transforming Growth Factor-β-Induced Expression of Vimentin Is an Independent Predictor of Biochemical Recurrence after Radical Prostatectomy (2009) (102)
Grading errors in prostatic needle biopsies: relation to the accuracy of tumor grade in predicting pelvic lymph node metastases. (1982) (102)
Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin. (1986) (101)
Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. (1994) (101)
Prostate specific antigen density correlates with features of prostate cancer aggressiveness. (2007) (100)
Primary treatment choices for men with clinically localized prostate carcinoma detected by screening (2000) (100)
Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study. (1998) (98)
Quality‐of‐life outcomes for men with prostate carcinoma detected by screening (2000) (98)
What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? (2011) (98)
Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. (1997) (98)
Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. (2003) (97)
Baseline prostate-specific antigen testing at a young age. (2012) (96)
Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder. (1986) (96)
Cellular immunity in cured cancer patients (1974) (95)
Clinical stage B prostate carcinoma: staging with MR imaging. (1987) (94)
Differences in values obtained with 2 assays of prostate specific antigen. (1988) (94)
Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. (2006) (93)
Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor. (1990) (93)
Familial aspects of prostate cancer: a case control study. (1995) (92)
Screening for prostate cancer in high risk populations. (2002) (91)
Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. (1998) (90)
Efficacy of first-generation Cavermap to verify location and function of cavernous nerves during radical prostatectomy: a multi-institutional evaluation by experienced surgeons. (2001) (88)
Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. range. (2002) (87)
Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. (1999) (87)
Clinical and pathological features of hereditary prostate cancer. (1996) (86)
Effect of mini-dose heparin on lymphocele formation following extraperitoneal pelvic lymphadenectomy. (1980) (86)
Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. (2014) (85)
Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. (2006) (85)
Prostate specific antigen velocity threshold for predicting prostate cancer in young men. (2007) (84)
Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates. (2005) (84)
Prophylactic mini-dose heparin in patients undergoing radical retropubic prostatectomy. A prospective trial. (1992) (82)
Emphysematous pyelonephritis: successful management by percutaneous drainage. (1986) (81)
Effect of adjuvant radiation therapy on prostate specific antigen following radical prostatectomy. (1990) (81)
Serum glycoproteins in cancer patients: First report of correlations with in vitro and in vivo parameters of cellular immunity (1980) (81)
Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity. (1983) (80)
What the U.S. Preventive Services Task Force Missed in Its Prostate Cancer Screening Recommendation (2012) (80)
Association of hemospermia with prostate cancer. (2004) (80)
Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies. (1996) (80)
The Melbourne Consensus Statement on the early detection of prostate cancer (2014) (78)
Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0 ng./ml. (1993) (77)
Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels. (1997) (77)
High-grade prostatic intraepithelial neoplasia in needle biopsy as risk factor for detection of adenocarcinoma: current level of risk in screening population. (2005) (77)
Targeting FOXA1-mediated repression of TGF-&bgr; signaling suppresses castration-resistant prostate cancer progression (2018) (76)
Prognostic factors in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer. (1988) (76)
Intermediate-term survival results in clinically understaged prostate cancer patients following radical prostatectomy. (1988) (76)
Prostate Cancer Screening. (2018) (75)
Prostate cancer early detection version 1 (2014) (75)
Role of lymphadenectomy in carcinoma of the penis. (1980) (75)
Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer. (1986) (75)
Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer (2017) (74)
Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer. (1999) (74)
Long-term follow-up of men undergoing modified inguinal lymphadenectomy for carcinoma of the penis. (1997) (73)
The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer. (1998) (73)
Serum alpha-fetoprotein and human chorionic gonadotropin in patients with seminoma. (1980) (73)
Abnormalities of cell-mediated immunocompetence in genitourinary cancer. (1974) (72)
Accuracy of frozen section detection of lymph node metastases in prostatic carcinoma. (1982) (72)
Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. (2001) (72)
Nerve-sparing radical retropubic prostatectomy. (1985) (71)
Under diagnosis and over diagnosis of prostate cancer. (2007) (71)
Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. (2002) (70)
Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. (1998) (70)
Delay of surgery in men with low risk prostate cancer. (2011) (69)
Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls. (2001) (68)
Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach. (2010) (68)
Nerve-Sparing Radical Prostatectomy (1989) (67)
Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma. (2001) (67)
Bladder neck contracture after retropubic radical prostatectomy: incidence and risk factors from a large single‐surgeon experience (2009) (66)
What to do with an abnormal PSA test. (2008) (66)
Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. (2009) (66)
Accuracy of prostate weight estimation by digital rectal examination versus transrectal ultrasonography. (2005) (66)
Vitamin D Deficiency Predicts Prostate Biopsy Outcomes (2014) (65)
The ability of systematic transrectal ultrasound guided biopsy to detect prostate cancer in men with the clinical diagnosis of benign prostatic hyperplasia. (1991) (65)
Genome‐wide scan of brothers: Replication and fine mapping of prostate cancer susceptibility and aggressiveness loci (2003) (65)
The PSA era is not over for prostate cancer. (2005) (64)
Retrospective comparison of radical retropubic prostatectomy and 125iodine brachytherapy for localized prostate cancer. (1999) (63)
TGF-β Regulates DNA Methyltransferase Expression in Prostate Cancer, Correlates with Aggressive Capabilities, and Predicts Disease Recurrence (2011) (62)
Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer. (2004) (61)
Racial differences in operating characteristics of prostate cancer screening tests. (1997) (61)
Quantitative dinitrochlorobenzene contact sensitization in a normal population. (1972) (61)
Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. (2013) (61)
Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer. (1986) (60)
Acute Preoperative Hemodilution in Patients Undergoing Radical Prostatectomy: A Case Study Analysis of Efficacy (1994) (60)
Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. (2005) (60)
Management of Superficial Bladder Cancer (1987) (59)
Using PSA to screen for prostate cancer. The Washington University experience. (1993) (59)
Mutational Landscape of Aggressive Prostate Tumors in African American Men. (2016) (58)
Treatment outcomes of radical prostatectomy in potential candidates for 3 published active surveillance protocols. (2010) (57)
Prostate cancer aggressiveness locus on chromosome segment 19q12–q13.1 identified by linkage and allelic imbalance studies (2003) (57)
Carcinoma of the prostate: a review. (1978) (56)
Falsely positive specific human chorionic gonadotropin assays in patients with testicular tumors: conversion to negative with testosterone administration. (1979) (56)
Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy (2000) (56)
Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years. (2005) (55)
Sonographic and pathological staging of patients with clinically localized prostate cancer. (1989) (55)
Autosomal dominant inheritance of prostate cancer: a confirmatory study. (2001) (55)
Re: Serum Prostate Specific Antigen as Pre-Screening Test for Prostate Cancer, by F. Labrie, A. Dupont, R. Suburu, L. Cusan, M. Tremblay, J.-L. Gomez and J. Emond, J. Urol., 147: 846–852, 1992 (1993) (55)
Racial differences in a prostate cancer screening study. (1996) (54)
Lymphocyte stimulation in urologic cancer patients. (1974) (54)
Suppression of cellular immunity by anesthesia and operation. (1977) (54)
Ureteral obstruction from prostatic carcinoma: response to endocrine and radiation therapy. (1977) (54)
Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. (2007) (54)
Diagnostic Value of Guided Biopsies: Fusion and Cognitive-registration Magnetic Resonance Imaging Versus Conventional Ultrasound Biopsy of the Prostate. (2016) (53)
Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial. (2000) (53)
Practical utility of specific red cell adherence test in bladder cancer. (1981) (53)
Viewpoint: Expanding Prostate Cancer Screening (2006) (53)
High resolution sonography in diagnosing testicular neoplasms: clinical significance of false positive scans. (1986) (53)
Patient preferences for outcomes associated with surgical management of prostate cancer. (2002) (53)
Prostate cancer diagnosis is associated with an increased risk of erectile dysfunction after prostate biopsy (2013) (52)
Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. (2010) (52)
Surgical management of prostate cancer. Contemporary results with anatomic radical prostatectomy (1995) (52)
Prostate cancer aggressiveness locus on chromosome 7q32-q33 identified by linkage and allelic imbalance studies. (2002) (52)
Role of nerve-sparing radical prostatectomy for clinical stage B2 prostate cancer. (1990) (52)
Technical factors affecting the reproducibility of intravesical mouse bladder tumor implantation during therapy with Bacillus Calmette-Guérin. (1984) (51)
Correlation of preoperative lymphocyte reactivity with the clinical course of cancer patients. (1973) (51)
Prostate cancer‐specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high‐risk factors (2007) (51)
Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy. (2005) (51)
Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. (2006) (51)
Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes. (2002) (50)
Endocrine therapy for bladder outlet obstruction from carcinoma of the prostate. (1985) (50)
Prostate Cancer Early Detection, Version 2.2015 (2015) (50)
Prostate‐specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer (2012) (49)
Outcomes in patients with Gleason score 8–10 prostate cancer: relation to preoperative PSA level (2012) (49)
Analysis of Candidate Genes for Prostate Cancer (2004) (48)
Transitional cell carcinoma of bladder in children and adolescents. (1993) (47)
Common variants in 8q24 are associated with risk for prostate cancer and tumor aggressiveness in men of European ancestry (2009) (47)
T lymphocytes in bladder and prostatic cancer patients. (1974) (46)
Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European origin (2007) (46)
Surgical management of prostate cancer (1995) (46)
Active Surveillance in Younger Men With Prostate Cancer. (2017) (46)
Extremely high values of prostate-specific antigen in patients with adenocarcinoma of the prostate; demonstration of the "hook effect". (1988) (46)
Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases (2015) (46)
Interrelationship of prealbumin and α‐1 acid glycoprotein in cancer patient sera (1977) (45)
APPROACHES TO URINARY DETECTION OF PROSTATE CANCER (2019) (45)
Transrectal ultrasonography in the diagnosis and staging of carcinoma of the prostate. (1988) (45)
Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA). (2009) (44)
Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures. (1997) (44)
Impact of age, benign prostatic hyperplasia, and cancer on prostate‐specific antigen level (2006) (43)
Complications of open radical retropubic prostatectomy in potential candidates for active monitoring. (2007) (43)
Identification and fine mapping of a region showing a high frequency of allelic imbalance on chromosome 16q23.2 that corresponds to a prostate cancer susceptibility locus. (2000) (43)
Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy. (2005) (42)
Diagnosis, staging, and surgical treatment of prostatic carcinoma. (1987) (42)
The Prostate Health Index: Its Utility in Prostate Cancer Detection. (2016) (42)
Characteristics of patients with familial versus sporadic prostate cancer. (2006) (41)
Prognostic value of host immunocompetence in urologic cancer patients. (1975) (41)
Comparison of the fibronectin-binding ability and antitumor efficacy of various mycobacteria. (1990) (40)
Inhibition of murine bladder tumor growth by bacille Calmette-Guerin: lack of a role of natural killer cells. (1986) (40)
More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects. (2004) (40)
Variants in the HEPSIN gene are associated with prostate cancer in men of European origin (2006) (40)
Screening for prostate cancer: enthusiasm. (1993) (40)
Surgical considerations in treatment of intraductal carcinoma of the prostate. (1978) (40)
Correlates of dissatisfaction with treatment in patients with prostate cancer diagnosed through screening. (1999) (39)
Pathological features after radical prostatectomy in potential candidates for active monitoring. (2007) (39)
Papaverine testing of impotent patients following nerve-sparing radical prostatectomy. (1987) (39)
Patient selection for, results of, and impact on tumor resection of potency-sparing radical prostatectomy. (1990) (38)
Replication linkage study for prostate cancer susceptibility genes (2000) (38)
Tumor characteristics of carriers and noncarriers of the deCODE 8q24 prostate cancer susceptibility alleles. (2008) (37)
Interferon induction and augmentation of natural-killer activity by Staphylococcus protein A. (1981) (37)
Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. (2004) (37)
Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection? (2010) (37)
Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. (2006) (37)
Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy? (2007) (37)
Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy. (2016) (37)
Correlation among host immunocompetence and tumor stage, tumor grade and vascular permeation in transitional carcinoma. (1973) (36)
Ultrasonic localization of a non-palpable testis tumor. (1979) (36)
Is statin use associated with prostate cancer aggressiveness? (2010) (36)
Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml. (2007) (36)
Personalized prostate specific antigen testing using genetic variants may reduce unnecessary prostate biopsies. (2013) (35)
Inflammatory Bowel Disease and the Risk of Prostate Cancer. (2018) (35)
Adenomatous polyps of the prostatic urethra: a cause of hematospermia. (1980) (35)
Genetic prostate cancer risk assessment: common variants in 9 genomic regions are associated with cumulative risk. (2010) (34)
Percutaneous nephrostomy: indications, complications and clinical usefulness. (1978) (34)
Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. (2008) (33)
Immunotherapy of superficial bladder cancer. (1982) (33)
Correlations among cutaneous reactivity to DNCB, PHA-induced lymphocyte blastogenesis and peripheral blood E rosettes. (1975) (33)
Preliminary report on 10 patients treated with radiotherapy after radical prostatectomy for isolated elevation of serum PSA levels. (1990) (32)
Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21 (2016) (32)
Germline sequencing DNA repair genes in 5,545 men with aggressive and non-aggressive prostate cancer. (2020) (31)
Familial medullary thyroid carcinoma, pheochromocytoma, and parathyroid adenoma (Sipple's syndrome) Study of a kindred (1971) (31)
NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015. (2015) (31)
Measurement of prostate-specific antigen as a screening test for prostate cancer (1991) (31)
Prostatic cancer, acid phosphatase, creatine kinase-BB and race: a prospective study. (1982) (30)
Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting. (1998) (30)
Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors. (1990) (30)
Is the utility of prostate‐specific antigen velocity for prostate cancer detection affected by age? (2008) (30)
The methodology used to measure differential gene expression affects the outcome. (2007) (29)
The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels. (1999) (29)
Malignant pheochromocytoma of the bladder: the late development of renal cell carcinoma. (1975) (28)
Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis. (2005) (28)
Adverse implications of acid phosphatase levels in the upper range of normal. (1987) (28)
EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells (2019) (28)
PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness. (2008) (28)
Comparison of methods for calculating prostate specific antigen velocity. (2006) (28)
Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease (2014) (27)
Use of prostate-specific antigen velocity to follow up patients with isolated high-grade prostatic intraepithelial neoplasia on prostate biopsy. (2007) (27)
Lymphovascular invasion in radical prostatectomy specimens: prediction of adverse pathologic features and biochemical progression. (2006) (27)
Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy. (2004) (27)
Cystotomy, temporary urinary diversion and bladder packing in the management of severe cyclophosphamide-induced hemorrhagic cystitis. (1990) (27)
Management of newly diagnosed metastatic carcinoma of the prostate. (1984) (26)
Effect of temporary occlusion of hypogastric arteries on blood loss during radical retropubic prostatectomy. (1991) (26)
Prostate specific antigen assay standardization bias could affect clinical decision making. (2008) (26)
Definitive Therapy for Localized Prostate Cancer-An Overview (2007) (26)
The epidemiology and clinical implications of genetic variation in prostate cancer. (2014) (26)
The association between total prostate specific antigen concentration and prostate specific antigen velocity. (2007) (26)
Prostate cancer screening and determining the appropriate prostate-specific antigen cutoff values. (2010) (26)
Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. (2020) (25)
Tumor markers in testicular cancer. (1979) (25)
An isolated plexiform neurofibroma of the bladder. (1985) (25)
What is the role of digital rectal examination in men undergoing serial screening of serum PSA levels? (2009) (25)
Early diagnosis of prostate cancer. (1987) (25)
Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median. (2007) (25)
Self-reported Black race predicts significant prostate cancer independent of clinical setting and clinical and socioeconomic risk factors. (2018) (25)
Predictors of mortality after androgen‐deprivation therapy in patients with rapidly rising prostate‐specific antigen levels after local therapy for prostate cancer (2006) (24)
History of the discovery and clinical translation of prostate-specific antigen (2014) (24)
Discordance among cell-mediated cytolytic mechanisms in cancer patients: importance of the assay system. (1979) (24)
Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action. (1990) (24)
Associations Between iCOGS Single Nucleotide Polymorphisms and Upgrading in Both Surgical and Active Surveillance Cohorts of Men with Prostate Cancer. (2016) (23)
Bladder carcinoma. (1980) (23)
Late decompensation of neobladder. (1992) (23)
Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomy. (2008) (23)
Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG) (2012) (23)
Renal oncocytoma with synchronous contralateral renal cell carcinoma. (1985) (23)
Prostate-specific antigen and screening for prostate cancer. (2004) (22)
Antegrade approach to radical retropubic prostatectomy in patients with difficult apical dissection. (1991) (22)
Concanavalin A-inducible suppressor cells in regional lymph nodes of cancer patients. (1979) (22)
Yield from routine prostatic needle biopsy in patients more than 50 years old referred for urologic evaluation: a preliminary report. (1980) (22)
New staging systems for prostate cancer. (1989) (22)
Complications of Radical Retropubic Prostatectomy (1990) (22)
Informed consent for prostate-specific antigen screening. (2003) (22)
Assay standardization bias: different prostate cancer detection rates and clinical outcomes resulting from different assays for free and total prostate-specific antigen. (2007) (21)
Occurrence of hernia of Morgagni with filial cervical lung hernia: a hereditary defect of the cervical mesenchyme? (1972) (21)
Outcomes of radical prostatectomy for patients with clinical stage T1a and T1b disease (2009) (20)
Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results. (2006) (20)
Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. (2006) (20)
External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series. (2012) (20)
The diagnosis and treatment of prostate cancer. (1991) (20)
Characterization of a method for profiling gene expression in cells recovered from intact human prostate tissue using RNA linear amplification (2006) (20)
Pelvic lymph node status as predictor of extracapsular tumor extension in clinical stage B prostatic cancer. (1983) (20)
Prostate-specific antigen screening: pro (2010) (20)
Effect of radiation therapy for urologic cancer on circulating thymus-derived lymphocytes. (1974) (20)
Carcinosarcoma of the prostate: report of a case with ultrastructural observations. (1979) (20)
Production of macrophage activation factor by a T-cell hybridoma. (1982) (20)
Genistein treatment duration effects biomarkers of cell motility in human prostate (2019) (19)
20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centers. (2009) (19)
A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session: Editorial comment (2003) (19)
Lack of value of radioimmunoassay for prostatic acid phosphatase as a screening test for prostatic cancer in patients with obstructive prostatic hyperplasia. (1983) (19)
Derivation and application of upper limits for prostate specific antigen in men aged 50-74 years with no clinical evidence of prostatic carcinoma. (1995) (19)
Radical surgery for advanced prostate cancer and for radiation failures. (1992) (19)
Production of gamma interferon by human T and null cells and its regulation by macrophages. (1982) (19)
The Utility of Prostate Specific Antigen Density, Prostate Health Index, and Prostate Health Index Density in Predicting Positive Prostate Biopsy Outcome is Dependent on the Prostate Biopsy Methods. (2019) (19)
Insertion of an SVA-E retrotransposon into the CASP8 gene is associated with protection against prostate cancer (2016) (18)
Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer. (2008) (18)
Demonstration of the existence of canine prostatic lymphatics by radioisotope techniques. (1977) (18)
Screening for prostate cancer (1994) (18)
Commentary on the immunobiology of bladder cancer. (1977) (17)
Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a “normal” prostate specific antigen and digital rectal examination (2011) (17)
Pathological outcomes associated with the 17q prostate cancer risk variants. (2009) (16)
Association of prostate cancer risk alleles with unfavourable pathological characteristics in potential candidates for active surveillance (2012) (16)
A genetic-based approach to personalized prostate cancer screening and treatment (2015) (16)
Choice of an optimal diluent for intravesical bacillus Calmette-Guerin administration. (1989) (16)
Genetic sequence variants are associated with severity of lower urinary tract symptoms and prostate cancer susceptibility. (2013) (16)
Intermediate term biochemical progression rates after radical prostatectomy and radiotherapy in patients with screen detected prostate cancer. (2005) (16)
Identification of complement-receptor lymphocytes (B cells) in lymph nodes and tumor infiltrates. (1975) (15)
Does Prostate Volume Correlate with Vitamin D Deficiency Among Men Undergoing Prostate Biopsy? (2016) (15)
Number of prostate cancer risk alleles may identify possibly ‘insignificant’ disease (2010) (15)
T-cell hybridoma production of macrophage activation factor (MAF) I. Separation of MAF from interferon gamma. (1982) (15)
Prostate-cancer screening. (2009) (15)
Genetics of prostate cancer. (2003) (15)
Strategy for improving therapy of superficial bladder cancer (1991) (15)
Bacteriuria and antibiotic resistance in catheter urine specimens following radical prostatectomy. (2013) (15)
Comparison of different serum prostate specific antigen measures for early prostate cancer detection (1994) (15)
Lack of specificity of lymphocyte-mediated cytotoxicity against the bladder cancer cell line, T24. (1977) (15)
Deciding whom to biopsy. (2010) (14)
Modification of lymphocyte responsiveness by hormone used in the treatment of urologic malignancies. (1976) (14)
Comparison of the efficacy of intravesical Bacillus Calmette-Guérin with thiotepa, mitomycin C, poly I:C/poly-L-lysine and cis platinum in murine bladder cancer. (1984) (14)
Prostate cancer risk alleles and their associations with other malignancies. (2011) (14)
Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG (2012) (14)
Embryonal rhabdomyosarcoma of the genitourinary organs. (1981) (13)
IS STATIN USE ASSOCIATED WITH PROSTATE CANCER AGGRESSIVENESS (2009) (13)
Correlation of immune reactivity and clinical status in cancer. (1974) (13)
Effects of carrageenan on spontaneous and antibody-dependent cell-mediated cytotoxicity. (1978) (13)
Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml. (2005) (13)
Tumors of the Prostate Gland (1985) (13)
WHICH IS THE MOST IMPORTANT RISK FACTOR FOR PROSTATE CANCER: RACE, FAMILY HISTORY, OR BASELINE PSA LEVEL? (2008) (13)
Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer (2008) (12)
TGFBR1*6A is not associated with prostate cancer in men of European ancestry (2005) (12)
Bilateral renal cell carcinoma with metastasis to thyroid. (1991) (12)
Prostate specific antigen testing. (2004) (12)
PSA and the Detection of Prostate Cancer-Reply (1994) (12)
HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer (2021) (12)
Surgical staging of genitourinary tumors (1987) (12)
National Cancer Institute Prostate Cancer Genetics Workshop. (2011) (11)
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG) (2012) (11)
Association between inflammatory bowel disease and prostate cancer: A large‐scale, prospective, population‐based study (2020) (11)
Effect of tumor necrosis factor and interferon gamma on human renal carcinoma cell line growth. (1989) (11)
Role of immunotherapy in the prevention of recurrence and invasion of urothelial bladder tumors: a review (1985) (11)
Results of compliance with prostate cancer screening guidelines. (2005) (11)
Editorial: Expectant Management and The Natural History of Localized Prostate Cancer (1994) (11)
A rare 8q24 single nucleotide polymorphism (SNP) predisposes North American men to prostate cancer and possibly more aggressive disease (2015) (11)
PSA enzymatic activity: A new biomarker for assessing prostate cancer aggressiveness (2013) (11)
Reducing blood loss in open radical retropubic prostatectomy with prophylactic periprostatic sutures (2009) (11)
Comparison of different serum prostate specific antigen measures for early prostate cancer detection. (1994) (11)
Prostate cancer risk alleles are associated with prostate cancer volume and prostate size. (2014) (11)
Therapeutic considerations in renal plasmacytoma. (1974) (11)
Fine‐mapping of prostate cancer aggressiveness loci on chromosome 7q22–35 (2011) (11)
Characteristics of prostate cancers detected at prostate specific antigen levels less than 2.5 ng/ml. (2009) (10)
Suprapubic tube after radical prostatectomy. (2013) (10)
New screening and diagnostic tests for prostate cancer and immunologic assessment. (1981) (10)
Concanavalin A-activated suppressor cell activity in peripheral blood lymphocytes of urologic cancer patients. (1980) (10)
Xanthogranulomatous pyelonephritis masquerading as occult malignancy. (1978) (10)
Immunobiology of carcinoma of the prostate. (1980) (9)
Clinical Urology: Letter to the EditorIn Reply: Re: Selection of Optimal Prostate Specific Antigen Cutoffs for Early Detection of Prostate Cancer: Receiver Operating Characteristic Curves (1996) (9)
Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort (2021) (9)
Antibody-dependent and spontaneous lympholysis in urologic cancer patients. (1979) (9)
SIRPB1 promotes prostate cancer cell proliferation via Akt activation (2020) (9)
Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies: Editorial comment (1990) (9)
GENETIC PROSTATE CANCER RISK ASSESSMENT: COMMON VARIANTS IN 9 GENOMIC REGIONS ARE ASSOCIATED WITH CUMULATIVE PROSTATE CANCER RISK AND AGGRESSIVE DISEASE (2009) (8)
Modification of Mitrofanoff principle for continent urinary diversion. (1993) (8)
BCG Therapy for Superficial Bladder Cancer (1984) (8)
Induction of human gamma interferon by protein A from Staphylococcus aureus. (1981) (8)
533: Baseline PSA Compared with Median PSA for Age Group as Predictor of Pathologic Tumor Features in Men < 60 Years of Age (2005) (7)
MP43-03 ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER: TIME TRENDS AND VARIATION IN THE AUA QUALITY (AQUA) REGISTRY (2022) (7)
DETECTION OF PROSTATE CANCER WITH %FPSA AND HK2 WHEN PSA IS 2-4 NG/ML (1999) (7)
1847 [-2]PROPSA IN COMBINATION WITH PSA AND FREE-PSA, USING THE BECKMAN COULTER ACCESS IMMUNOASSAY SYSTEMS IMPROVES PROSTATE CANCER DETECTION RELATIVE TO PSA AND FREE PSA. A MULTI-CENTER PROSPECTIVE CLINICAL STUDY (2010) (7)
Quantitative dinitrochlorobenzene contact sensitivity in preoperative and cured cancer patients. (1973) (7)
Effects of chemotherapy for prostatic carcinoma on T lymphocyte levels. (1974) (7)
949: Serum PSA Correlates More Strongly with Percentage of Cancer and Cancer Volume than with Prostate Size (2005) (7)
Serum ribonuclease in urologic cancer. Relation to host immunocompetence. (1973) (7)
Host immunocompetence in genitourinary cancer: relation to tumor stage and prognosis. (1978) (7)
Erratum: High-throughput oncogene mutation profiling in human cancer (Nature Genetics (2007) 39, (347-351)) (2007) (7)
Current management of testicular tumors. (1982) (7)
Erratum: Corrigendum: High-throughput oncogene mutation profiling in human cancer (2007) (7)
20–25% Lower Concentrations of Total and Free Prostate-Specific Antigen (PSA) after Calibration of PSA Assays to the WHO Reference Materials – Analysis of 1098 Patients in Four Centers (2009) (7)
The United States Preventive Services Task Force Recommendation against Prostate-Specific Antigen Screening—Counterpoint (2012) (7)
Prostate cancer screening (2004) (7)
Genetic factors associated with prostate cancer conversion from active surveillance to treatment (2021) (7)
Preventive health services. (1994) (7)
Targeting FOXA 1-mediated repression of TGF-b signaling suppresses castration-resistant prostate cancer progression (2019) (7)
Does diabetes mellitus modify the association between 17q12 risk variant and prostate cancer aggressiveness? (2009) (6)
Expression and initial promoter characterization of PCAN1 in retinal tissue and prostate cell lines (2004) (6)
Preoperative prostate specific antigen doubling time is not a useful predictor of biochemical progression after radical prostatectomy. (2010) (6)
Treatment strategies for prostate cancer. (1993) (6)
Identification of a gene frequently mutated in prostate tumors (2001) (6)
Ownership and use of tissue specimens for research. (2005) (6)
Genetically adjusted prostate‐specific antigen values may prevent delayed biopsies in African‐American men (2014) (6)
471: PSA Velocity Threshold for Predicting Prostate Cancer in Young Men with PSA < 4 ng/ml (2006) (6)
Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer. (2008) (6)
Re: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. (1992) (6)
953: Age-Specific Risk of Prostate Cancer if PSA is between the Median Value and Commonly Used Biopsy Thresholds (2005) (6)
Immediate radical prostatectomy in patients with atypical small acinar proliferation. Over treatment?: Editorial comment (2004) (6)
Re: Modified Inguinal Lymphadenectomy for Carcinoma of the Penis with Preservation of Saphenous Veins: Technique and Preliminary Resuts, by W.J. Catalona, J. Urol., 140: 306-310, 1988 (1988) (6)
470: Perineural Invasion: Surrogate Marker for the Extent of Cancer in Radical Prostatectomy Specimens (2005) (6)
Open radical retropubic prostatectomy. (2007) (5)
Sodium wasting in potassium depletion: the role of aldosterone. (1972) (5)
Comparison of quantitative and classic prognosticators in urinary bladder carcinoma: A multivariate analysis of DNA flow cytometric, nuclear morphometric and clinicopathological features: Editorial comment (1990) (5)
Specificity of in vitro cellular cytotoxicity against transitional cell carcinoma cell line T-24. (1975) (5)
Screening for prostate cancer. (1995) (5)
Acute pyelonephritis simulating poorly vascularized renal neoplasm. Non-specificity of angiographic criteria. (1976) (5)
Correlation between Serum PSA and Cancer Volume in Prostate Glands of Different Sizes (2010) (5)
The association of phosphodiesterase-5 inhibitors with the biochemical recurrence-free and overall survival of patients with prostate cancer following radical prostatectomy. (2021) (5)
Transitional cell carcinoma in a pyelogenic cyst. (1977) (5)
Advances in Brief CDKN 1 A and CDKN 1 B Polymorphisms and Risk of Advanced Prostate Carcinoma 1 (2003) (5)
Interrelationship of prealbumin and alpha-1 acid glycoprotein in cancer patient sera. (1977) (5)
Free serum prostate-specific antigen and screening for prostate cancer. (1996) (5)
The influence of serial prostate‐specific antigen (PSA) screening on the PSA velocity at diagnosis (2008) (5)
Statin use and risk of prostate cancer biochemical recurrence after radical prostatectomy. (2020) (5)
Heightened Interferon-γ Production by Mononuclear Cells from Bladder Cancer Patients (1984) (4)
What is the prognostic impact of positive surgical margins in surgically treated prostate cancer? (2006) (4)
Prostate cancer. (1990) (4)
Catecholamine excess: Probable cause of postoperative tachycardia following retroperitoneal lymph node dissection (RPLND) for testicular carcinoma (1989) (4)
469: Comparison of Different Methods for Calculating PSA Velocity: Importance of Time Interval Prior to Diagnosis of Prostate Cancer (2005) (4)
Concanavalin A-activated suppressor cells in peripheral blood and lymph nodes of urologic cancer patients. (1978) (4)
DNCB test in cancer patients. (1972) (4)
Prostate-specific antigen (PSA) should drive doing prostate biopsies. (2012) (4)
Screening for early detection of prostate cancer (1996) (4)
Interferon as an Antitumor Agent for Urologic Tumors (1984) (4)
Immunology of Genitourinary Tumors (1982) (4)
TOTAL PSA CUTOFF OF 2.5 NG./ML. CORRELATES WITH FAVORABLE PATHOLOGIC FEATURES OF PROSTATE CANCER (1999) (4)
Principles of Oncology and Immunology, and Tumors of Bladder, Penis and Urethra (1990) (4)
Screening for prostate cancer [2] (1995) (4)
476: Underdiagnosis and Overdiagnosis of Prostate Cancer (2006) (4)
SHOULD A FAMILY HISTORY OF PROSTATE CANCER AFFECT THE TOTAL PSA OR PSA VELOCITY THRESHOLD FOR BIOPSY (2008) (4)
Definitive Therapy for Localized Prostate Cancer (2012) (4)
Association between inflammatory bowel disease and prostate cancer: A large-scale, prospective, population-based study (2020) (4)
Screening for prostate cancer. Early screening is important despite lack of data from trials. (1997) (3)
Staging of Prostatic Carcinoma (1989) (3)
Prostate cancer: The growing evidence supporting mid-life PSA testing (2013) (3)
125: Does Body Mass Index Affect Outcomes Following Radical Prostatectomy? (2006) (3)
Words of wisdom. Re: Radical prostatectomy versus observation for localized prostate cancer. (2012) (3)
Clinical value of longitudinal free-to-total prostate specific antigen ratio slope to diagnosis of prostate cancer. (2004) (3)
Re: Modified inguinal lymphadenectomy for carcinoma of the penis with preservation of saphenous veins: technique and preliminary results. (1988) (3)
Grading and Staging of Prostate Cancer (1982) (3)
Mutant L Homologue 1 (MLH1): a possible new immunohistochemical marker for prostatic cancer (2007) (3)
Potency-Sparing Surgery for Localized Prostate Cancer (1987) (3)
327: Updated Recurrence-Free Survival (RFS) Prediction Model Following Radical Prostatectomy (RRP) (2007) (3)
An incision for extended suprahilar retroperitoneal lymphadenectomy. (1978) (3)
A multiparametric approach to improve upon existing prostate cancer screening and biopsy recommendations (2017) (3)
Expectant management and the natural history of localized prostate cancer. (1994) (3)
1875: Comparison between the Prostate Cancer Risk Calculator and Serum PSA (2007) (3)
Common Variants in 8q24 and MYC Oncogene are Associated with Risk for Prostate Cancer and Tumor Aggressiveness in Men of European Ancestry (2013) (3)
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse: Editorial comment (1990) (2)
854 SCREENING HISTORY OF MEN WITH FATAL PROSTATE CANCER (2010) (2)
The Influence of Decision Aids on Prostate Cancer Screening Preferences: A Randomized Survey Study (2018) (2)
DO THE 3 SIGNIFICANT 8q24 PROSTATE CANCER SUSCEPTIBILITY REGIONS PREDICT AGGRESSIVE DISEASE (2008) (2)
Conservative Management of Low-Risk Prostate Cancer: A Path to Value-Based Care. (2022) (2)
Re: Pathological stage is higher in older men with clinical stage B1 adenocarcinoma of the prostate. (1990) (2)
Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas: Editorial comment (1990) (2)
TechnicalFactorsAffectingthe Reproducibility of IntravesicalMouse BladderTumorImplantation duringTherapywithBacillusCalmette- GuÃ©r/n1 (1984) (2)
2324 GENETIC RISK ALLELES CAN PREDICT ACTIVE SURVEILLANCE FAILURES (2011) (2)
Penectomy and Inguinal Lymphadenectomy for Carcinoma of the Penis (1991) (2)
When is intervention warranted? (1992) (2)
Open Radical Retropubic Prostatectomy: Technique and Outcomes (2009) (2)
PROPSA IS MORE ACCURATE:PROSPECTIVE PROSTATE CANCER SCREENING STUDY COMPARING [-2]-PROPSA WITH FREE AND TOTAL PSA (2009) (2)
Operating characteristics of prostate-specific antigen and verification bias. (2005) (2)
Prostate cancer: Utility of the Riskindicator model in screening (2010) (2)
Suppressive effects of regional lymph node cells and extracts of antibody-dependent cellular cytotoxicity. (1978) (2)
Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma: Editorial comment (1990) (2)
Current management of iatrogenic splenic injuries in children. (1981) (2)
DECLARING A MORATORIUM ON REPEAT BIOPSIES: A NEW STATISTICAL METHOD FOR PREDICTING WHEN REPEAT PROSTATE BIOPSIES ARE UNNECESSARY (2008) (2)
Role of antibody in cytotoxicity by lymphocytes armed against 253J bladder cancer line. (1981) (2)
WHAT IS THE BEST TREATMENT FOR CLINICALLY LOCALIZED PROSTATE CANCER: RADICAL PROSTATECTOMY, BRACHYTHERAPY, OR EXTERNAL BEAM RADIATION THERAPY? (2008) (2)
Acute Normovolemic Hemodilution Is a Cost-effective Alternative to Preoperative Autologous Blood Donation (1994) (2)
Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer (2021) (2)
Bacille Calmette-Guerin intravesical therapy for superficial bladder cancer (1984) (2)
The outlook for preserving continence and potency during radical prostatectomy. (1994) (2)
Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: A matched comparison (1999) (2)
1144: Pre-Treatment PSA Velocity and Risk of Cancer Progression Following Radiation Therapy for Prostate Cancer (2005) (2)
Five and Seven Year Survival Results of Radical Prostatectomy in Clinically Understaged Stage A and B Prostate Cancer Patients (1987) (2)
Editorial Comment: The Free-to-Total Prostate Specific Antigen Ratio Improves the Specificity of Prostate Specific Antigen in Screening for Prostate Cancer in the General Population (1997) (2)
1432: Could Laser Vaporization of the Prostate for BPH Compromise Prostate Cancer Detection? (2006) (2)
Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US (2023) (2)
Is Early or Delayed Androgen Deprivation Best (1987) (2)
DIFFERENCES IN PSA MEASUREMENTS DUE TO ASSAY STANDARDIZATION BIAS (2008) (2)
PROSTATE-SPECIFIC ANTIGEN VELOCITY RISK COUNT FOR PREDICTION OF RADICAL PROSTATECTOMY OUTCOMES (2009) (2)
475: Do Most Patients with a PSA-Detected Prostate Cancer and a Very Large Prostate Gland Have a “Clinically Insignificant” Tumor? (2005) (2)
Detection of early prostate cancer: serendipitous or systematic? (1998) (2)
632: Two Distinct Types of Prostate Cancer are Detected with Digital Rectal Examination at PSA Levels Below 2.6 NG/ML (2004) (2)
Radical prostatectomy: Should the retropubic approach remain the standard of care? (2004) (2)
Pelvic lymphadenectomy is essential to staging accuracy in most patients with stages A-2 and B prostate cancer before radical prostatectomy. (1983) (2)
Genitourinary Cancer: Basic And Clinical Aspects (2011) (2)
534: PSA Velocity Cutoff for Recommending Biopsy: Positive Predictive Values (2005) (2)
2055 PROSTATE HEALTH INDEX (PHI) FOR REDUCING OVERDETECTION OF INDOLENT PROSTATE CANCER AND UNNECESSARY BIOPSY WHILE IMPROVING DETECTION OF AGGRESSIVE CANCERS (2013) (2)
814: Prediction of Advanced Prostate Cancer Using Biopsy Parameters: The Contribution of Tumor Percentage, Volume and the Number of Positive Biopsy Cores (2005) (2)
Advances in laboratory innovations and clinical management, with emphasis on innovations allowing bladder-sparing approaches for patients with invasive tumors: Editorial comment (1990) (1)
2043 PROSTATE-SPECIFIC ANTIGEN VELOCITY RISK COUNT IMPROVES THE SPECIFICITY OF SCREENING FOR CLINICALLY SIGNIFICANT PROSTATE CANCER (2010) (1)
A NEW STATISTICAL MODEL FOR TIME-DEPENDENT COVARIATES TO QUANTIFY RISK FOR REPEAT BIOPSY IN PATIENTS WITH ATYPICAL GLANDS SUSPICIOUS FOR CARCINOMA OR PROSTATIC INTRAEPITHELIAL NEOPLASIA (PIN) (2008) (1)
524: PSA Velocity to Follow Patients with Isolated Highgrade Pin on Prostate Biopsy (2006) (1)
Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men. (2022) (1)
NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023. (2023) (1)
Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation (2023) (1)
The Postal Service and cancer screening. (1999) (1)
609 HOSPITALIZATION FOR FEVER AFTER TRANSRECTAL ULTRASOUND-GUIDED PROSTATE NEEDLE BIOPSY (2010) (1)
Effect of Clamping Hypogastric Arteries on Perioperatiave Blood Loss During Radical Retropubic Prostatectomy (1987) (1)
Genital HPV infections in men: Editorial comment (1990) (1)
Tumor Markers in Prostatic Cancer (1983) (1)
982 EVALUATION OF THE PROSTATE HEALTH INDEX (PHI)1 IN THE 2 TO 4, AND 4 TO 10 NG/ML PSA RANGES: RESULTS FROM A MULTI-SITE, PROSPECTIVE, CLINICAL EVALUATION (2011) (1)
Use of statins and the risk of prostate cancer biochemical recurrence in men treated with radical prostatectomy. (2016) (1)
1209 PERSONALIZED PSA TESTING USING GENETIC VARIANTS CAN POSSIBLY DECREASE THE NUMBER OF PROSTATE BIOPSIES (2012) (1)
Baseline PSA testing for men in their 40s: currently available evidence strongly supports baseline PSA measurements in this age group. (2014) (1)
Implementing Continuous Quality Improvement in an Integrated Community Urology Practice: Lessons Learned. (2021) (1)
Prostate-specific antigen in black men. (1997) (1)
LONG-TERM BIOCHEMICAL “CURE” RATES WITH INITIAL OBSERVATION AND DELAYED SALVAGE RADIOTHERAPY AFTER RADICAL PROSTATECTOMY FOR HIGH-RISK PROSTATE CANCER (2008) (1)
RE: ASSOCIATION OF HEMOSPERMIA WITH PROSTATE CANCER (2005) (1)
2286 FREQUENCIES OF PROSTATE CANCER RISK VARIANTS IN EARLY ONSET AND FAMILIAL PROSTATE CANCER (2011) (1)
Heightened interferon-gamma production by mononuclear cells from bladder cancer patients. (1984) (1)
Monocyte cytolytic factor in promoting monocyte-mediated lysis of bladder cancer cells by bacillus Calmette-Guerin. (1987) (1)
Cancer of the prostate. (1992) (1)
Screening for prostate cancer. (1995) (1)
983 LONG-TERM 5-ALPHA REDUCTASE INHIBITOR USE IS ASSOCIATED WITH ADVERSE CLINICO-PATHOLOGIC FEATURES OF PROSTATE CANCER (2011) (1)
Characterization of cell-mediated cytolytic mechanisms against human transitional cell carcinoma line, 253J. (1980) (1)
1454: Salvage Radiation Therapy for PSA Progression Following Radical Prostatectomy: 10-Year Outcome Estimates (2004) (1)
1026: Combined PSA Density and Biopsy Features to Predict "Clinically Insignificant" Prostate Cancer (2007) (1)
Accuracy of Grading and Staging Prostate Cancer (1988) (1)
T rosette assay: in vitro correlate of cellular immunity. (1974) (1)
SERUM COMPLEX PSA IMPROVE CANCER DETECTION (2003) (1)
PROSPECTIVE RANDOMIZED TRIAL COMPARING 6 VERSUS 12 CORES: EFFECT ON CANCER DETECTION (1999) (1)
1261: Should PSA Prompt for Biopsy also be Lowered for Older Men? (2004) (1)
CAUSES OF DEATH IN PATIENTS WITH SCREEN-DETECTED PROSTATE CANCER (2009) (1)
1611: PSA Density Correlates with Features of Prostate Cancer Aggressiveness (2005) (1)
Early versus delayed intervention for prostate cancer: the case for early intervention (2007) (1)
Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment (2021) (1)
1179: Comparison of Radical Prostatectomy, Radiotherapy, Hormonal Therapy, and Watchful Waiting for Screen-Detected Prostate Cancer: an Update (2004) (1)
1755: Correlation between Digital Rectal Examination Findings and Pathological Findings in the Radical Prostatectomy Specimen (2007) (1)
1803 PROSTATE CANCER DIAGNOSIS IS ASSOCIATED WITH AN INCREASED RISK OF ERECTILE DYSFUNCTION FOLLOWING PROSTATE BIOPSY (2011) (1)
Prostate-Specific Antigen and Prostate Cancer Screening (2008) (1)
Gene profiling of genistein’s effect in men with prostate cancer. (2006) (1)
MP53-04 SIGNIFICANT INTER-INSTITUTIONAL VARIATIONS IN RACIAL DISPARITIES AMONG AFRICAN-AMERICAN MEN ELIGIBLE FOR PROSTATE CANCER ACTIVE SURVEILLANCE (2015) (1)
Modified groin lymphadenectomy for carcinoma of the penis (1988) (1)
Making prostate-specific antigen testing more effective. (2006) (1)
Reply to P.F. Pinksy (2011) (1)
1394: Organ-Confined Prostate Cancer is Common when Low- Volume Gleason Sum 8 To10 Cancer is Found in Biopsy Specimens (2006) (1)
The argument to continue prostate cancer screening, early detection (2012) (1)
Prostate Cancer Screening-Reply (1997) (1)
INCREASING INCIDENCE OF NO RESIDUAL AND LOW VOLUME PROSTATE CANCER: A STUDY OF 1792 RADICAL PROSTATECTOMIES (2008) (1)
1880: Update of Longitudinal Screening Study for Prostate Cancer with Prostate-Specific Antigen and Digital Rectal Examination (2007) (1)
Screening for prostate cancer. (1996) (1)
Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG) (2011) (1)
1420: Is the Utility of PSA Velocity for Prostate Cancer Detection Affected by Age? (2007) (1)
Host-tumor interactions during 5-fluorouracil therapy for prostatic carcinoma. (1974) (1)
Impact of use of phosphodiesterase type 5 inhibitors (PDE5-I) after radical prostatectomy (RP) on biochemical recurrence-free (BCRF) and overall survival (OS): A retrospective study from the Northwestern University SPORE in prostate cancer. (2017) (1)
IS PSA VELOCITY USEFUL FOR PROSTATE CANCER DETECTION OR PROGNOSTICATION IN MEN WITH A PSA > 10 NG/ML? (2009) (1)
Current management of prostatic carcinoma. (1985) (1)
Genetic ancestry and odds of prostate cancer diagnosis in African American and European American men. (2016) (1)
The management of stage A (T0) prostatic carcinoma (1989) (1)
Proceedings: Cellular immunity in cured cancer patients. (1974) (1)
COMMON VARIANTS ON MLH1 GENE AND THEIR ASSOCIATIONS WITH PROSTATE CANCER IN EUROPEAN AMERICANS (2008) (1)
Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer: Editorial comment (1990) (1)
1730 WHAT IS THE TRUE NUMBER-NEEDED-TO-SCREEN AND TREAT TO SAVE A LIFE WITH PSA SCREENING? (2010) (1)
CHARACTERISTICS OF PROSTATE CANCERS DETECTED AT LOW PSA VALUES (2008) (1)
1461: Predictors of Subsequent Prostate Cancer in Men with a PSA Level of 2.6-4.0 NG/ML and an Initially Negative Biopsy (2005) (0)
Characterization of the lymphocyte subpopulation producing interferon gamma after stimulation by protein A from staphylococcus aureus (1981) (0)
Characterization of interferon induced in human lymphocytes by staphylococcal protein A (1980) (0)
The epidermal growth factor receptor and the prognosis of bladder cancer: Editorial comment (1990) (0)
MP64-18 RISK OF PROSTATE CANCER IN MEN WITH CHRONIC INFLAMMATORY CONDITIONS (2020) (0)
Human papillomavirus detection in urine samples from male patients by the polymerase chain reaction: Editorial comment (1990) (0)
Bilateral Retroperitoneal Lymphadenectomy for Testicular Cancer with Preservation of the Lumbar Sympathetics (1987) (0)
1459: Comparison of Radical Prostatectomy, Radiotherapy, and Hormonal Therapy for Screen-Detected Prostate Cancer (2005) (0)
1740 GENETICS VARIANTS THAT INCREASE SEVERE LOWER URINARY TRACT SYMPTOMS IN AFRICAN-AMERICAN MEN (2013) (0)
Reply by Authors. (2021) (0)
Patient experiences with tissue-based genomic testing during active surveillance for prostate cancer. (2023) (0)
Editorial comment. (2010) (0)
984 ASSOCIATION BETWEEN PROSTATE CANCER SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) AND AGGRESSIVE DISEASE IN THE NATIONAL CANCER INSTITUTE GENETICS WORKING GROUP COHORT (2013) (0)
2063 CHARACTERISTICS AND PREDICTORS OF PROSTATE NEEDLE BIOPSY COMPLIANCE (2013) (0)
90 COMPARISON OF 2 DIFFERENT METHODOLOGIES USED TO DETERMINE INTERACTIONS BETWEEN PROSTATE CANCER SUCEPTIBILITY VARIANTS (2010) (0)
Lymphadenectomy in The Management of Carcinoma of the Penis (1989) (0)
Management of Patients with Stage B2 Prostate Cancer (1985) (0)
Long-term versus short-term doxorubicin hydrochloride instillation after transurethral resection of superficial bladder cancer: Editorial comment (1990) (0)
Approaches to urinary detection of prostate cancer (2019) (0)
Carcinoma of the Prostate - Clinical Stage C (1980) (0)
Abstract 331: SIRPB1 promotes prostate cancer cell proliferation & migration (2017) (0)
795: Is Perineural Invasion an Independent Predictor of Biochemical Progression in Patients with Organ Confined Disease After Radical Prostatectomy? (2004) (0)
Intravesical bacillus Calmette-Guerin treatment for superficial bladder tumours: Editorial comment (1990) (0)
Contents Vol. 57, 2004 (2004) (0)
1745: PSA velocity in Men with Total PSA Levels Less than 4 ng/ml (2007) (0)
Extended Suprahilar Retroperitoneal Lymphadenectomy for Testicular Cancer (1982) (0)
650: Progression-Free Survival Rates for Radical Prostatectomy in the PSA ERA (2006) (0)
450: Clinicopathologic Characteristics of Patients with Familial Prostate Cancer Versus Sporadic Cases (2004) (0)
Book ReviewRehabilitation Oncology Sexual Rehabilitation of the Urologic Cancer Patient (1981) (0)
PSA Thresholds for Prostate Cancer Detection-Reply (1997) (0)
GENETIC RISK SCORE CAN DISTINGUISH RISK OF PROSTATE CANCER AMONG FAMILY MEMBERS WITH SIMILAR DEGREES OF RELATIONSHIP: MP33‐11 (2017) (0)
Detection of numerical chromosome aberrations in bladder cancer by in situ hybridization: Editorial comment (1990) (0)
799: Does Transurethral Resection of Prostate (TURP) Compromise the Subsequent Radical Retropubic Prostatectomy (RRP) Outcomes? (2004) (0)
PSA Levels Give Clues to Prostatic Cancer (1991) (0)
Reply to E. Roca et al. (2016) (0)
848: Outcomes of Radical Prostatectomy in Potential Candidates for Active Monitoring (2007) (0)
123 GENETIC VARIANTS SIGNIFICANTLY IMPROVE DETECTION OF PROSTATE CANCER AND ARE ASSOCIATED WITH AGGRESSIVE FEATURES IN PATIENTS WITH A “NORMAL” PSA AND DRE (2010) (0)
449: The Association Between Hematospermia and Prostate Cancer (2004) (0)
BLADDER NECK CONTRACTURE AFTER RADICAL RETROPUBIC PROSTATECTOMY: INCIDENCE AND RISK FACTORS FROM A LARGE SINGLE-SURGEON EXPERIENCE (2008) (0)
2034 ASSOCIATION OF PROSTATE CANCER RISK ALLELES WITH PATHOLOGY UP-GRADING AT RADICAL PROSTATECTOMY (2011) (0)
MISCELLNEOUS: Discordance among cell-mediated cytolytic mechanisms in cancer patients (1981) (0)
1722 USE OF PSA DERIVATIVES TO DETERMINE THE NEED FOR REPEAT BIOPSY (2010) (0)
Transrectal Ultrasonography in the Staging of Prostate Cancer (1989) (0)
URINARY FUNCTION AND BOTHER (1999) (0)
Adult Urology mproved Stage and Grade-Specific rogression-Free Survival Rates After adical Prostatectomy in the PSA Era (2007) (0)
857: The Association between Total PSA and PSA Velocity (2006) (0)
1482: Performance Characteristics of PSA Density for Prostate Cancer Screening (2006) (0)
Defining Quality Metrics for Active Surveillance: The Michigan Urological Surgery Improvement Collaborative Experience. Letter. (2021) (0)
Separation of macrophage activation factor and gamma interferon (1982) (0)
485: PSA-Velocity Increases Continuously in the Years Prior to Diagnosis of Prostate Cancer (2006) (0)
865: Comparison of Preoperative PSA Velocity or PSA Doubling Time as a Predictor of Outcome after Radical Prostatectomy (2006) (0)
1613 EXTRACELLULAR SIGNAL-REGULATED KINASES IS AN IMPORTANT FACTOR INVOLVED IN THE DEVELOPMENT OF BENIGN PROSTATE (2013) (0)
Prostate Cancer Update 2022 (2022) (0)
Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma: Editorial comment (1990) (0)
Diagnosis and management of superficial bladder cancer: Editorial comment (1990) (0)
The Prevalence and Nature of Orgasmic Dysfunction After Radical Prostatectomy (2005) (0)
PROSTATE CANCER SCREENING. AUTHORS' REPLY (1997) (0)
Prostate cancer screening [7] (multple letters) (1997) (0)
Should an isolated humeral lesion detected during prostate cancer metastatic survey be biopsied? (2004) (0)
1595: Histopathologic Features of Prostate Tumors Detected at Different PSA Levels in the Contemporary PSA Era (2005) (0)
PSA THRESHOLDS FOR PROSTATE CANCER DETECTION. AUTHORS' REPLY (1997) (0)
Inflammatory bowel disease and risk of prostate cancer: A matched-cohort analysis. (2019) (0)
1310 SUPPRESSION OF CD8+ T CELL INFILTRATION BY INCREASED TGF-β EXPRESSION IS ASSOCIATED WITH BIOCHEMICAL RECURRENCE IN PROSTATE CANCER PATIENTS WITH LOW GLEASON SCORES (2012) (0)
Focal HIFU for prostate cancer. (2012) (0)
Neoadjuvant therapy for invasive bladder cancer: Editorial comment (1990) (0)
92 PROSTATE CANCER RISK VARIANTS ASSOCIATED WITH SUSCEPTIBILITY TO OTHER MALIGNANCIES (2010) (0)
2026 VALUE OF FIRST PSA IS ASSOCIATED WITH REGULARITY OF SUBSEQUENT PSA TESTING (2011) (0)
1842 EVALUATION OF NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) GUIDELINES FOR PROSTATE CANCER SCREENING AND DETECTION (2010) (0)
TRIAL OF EMPIRIC ANTIBIOTICS PRIOR TO RECOMMENDING BIOPSY FOR PSA ELEVATION HELPS STRATIFY PROSTATE CANCER RISK (2009) (0)
Editorial comment. (2013) (0)
732 GENISTEIN INHIBITS PROSTATE CANCER METASTASIS BY PREVENTING CELL DETACHMENT (2011) (0)
Abstract 688: Multi-stage exome sequencing study of 17,546 aggressive and non-aggressive prostate cancer cases (2022) (0)
Refined testing and targeted therapy lead new fight against prostate cancer. Interview by Wayne Kuznar. (1999) (0)
Invited commentary (2005) (0)
New concepts in the early detection of prostate cancer (2005) (0)
Anatomic nerve-sparing radical retropubic prostatectomy (2005) (0)
1141: Predicting Adverse Pathology and Cancer Progression: Comparison of Tumor Volume, Perineural Invasion, Percent Cancer and Lymphovascular Invasion in Radical Prostatectomy Specimen (2005) (0)
137 EVALUATION OF [-2]PROPSA IN COMBINATION WITH PSA AND FREE PSA, USING THE BECKMAN COULTER ACCESS IMMUNOASSAY SYSTEMS, FOR IDENTIFYING PATIENTS WITH AGGRESSIVE PROSTATE CANCER. A MULTI-CENTER PROSPECTIVE CLINICAL EVALUATION (2010) (0)
156: Variants in the Kallikrein (KLK) Gene Cluster and Epithelial Membrane Protein 3 (EMP3) on 19Q13 are Associated with Prostate Cancer in Men of Caucasian Ancestry (2007) (0)
No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam): Editorial comment (2004) (0)
130 CIRCULATING TUMOR CELLS IN PROSTATE CANCER PATIENTS: NOVEL IMMUNOMAGNETIC ENRICHMENT METHOD (2011) (0)
SURGICAL MANAGEMENT OF PROSTATE CANCER. AUTHOR'S REPLY (1995) (0)
Subject Index Vol. 57, 2004 (2004) (0)
GENETIC VARIATION ON 8q24 AND SUSCEPTIBILITY TO PROSTATE CANCER IN CAUCASIAN MEN (2008) (0)
2058 TOWARD A PERSONALIZED APPROACH TO PSA SCREENING: THE RELATIONSHIP BETWEEN RISK FACTORS AND PSA TESTING FREQUENCY (2013) (0)
989 A RARE GENETIC VARIANT ON CHROMOSOME 8Q24 THAT CONFERS A SIGNIFICANTLY GREATER RISK OF PROSTATE CANCER (2013) (0)
MP06-11 IMPLEMENTATION OF A PAY-FOR-PERFORMANCE MODEL TO ENHANCE THE UPTAKE OF CONSERVATIVE MANAGEMENT FOR LOW-RISK PROSTATE CANCER (2023) (0)
The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer: Editorial comment (II) (1990) (0)
Reply from Authors re: Seth A. Strope, Gerald L. Andriole. Prostate-Specific Antigen–Based Risk Assessment in Younger Men. Eur Urol 2012;61:8–9 (2012) (0)
Prostate Cancer Screening with Prostate-Specific Antigen Testing: More Answers or More Confusion? (2010) (0)
1614: Proenzyme Forms of Prostate Specific Antigen (PRO-PSA) are Associated with Progression-Free Survival Rate after Radical Prostatectomy (2007) (0)
Counterpoint: the case for immediate active treatment. (2007) (0)
Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases (2015) (0)
Words of wisdom. Re: Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. (2013) (0)
Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease (2013) (0)
CORRELATION OF PSA TO CANCER VOLUME IN PROSTATE GLANDS OF DIFFERENT SIZES (2009) (0)
AGE- AND RACE-SPECIFIC RESULTS OF A LARGE COMMUNITY BASED PROSTATE CANCER SCREENING STUDY (2009) (0)
PREOPERATIVE LEUPROLIDE MAY AFFECT POTENCY FOLLOWING NERVE-SPARING RADICAL PROSTATECTOMY (2009) (0)
108 COMPARISON OF CONVENTIONAL PSA AND NANOTECHNOLOGY PSA IN INDIVIDUAL PROSTATE CANCER PATIENTS (2010) (0)
A vision for closing the evidence-practice gap in the management of low-grade prostate cancer (2023) (0)
Routine excretory urography in follow-up of superficial transitional cell carcinoma of bladder: Editorial comment (1990) (0)
Comparative study of systemic interferon alfa-nl and isotretinoin in the treatment of resistant condylomata acuminata: Editorial comment (1990) (0)
992 GENETIC CORRECTION OF PSA LEVELS AND PROSTATE CANCER RISK MARKERS IMPROVE POSITIVE PREDICTIVE VALUE OF THE PSA TEST (2011) (0)
Current concepts in the management of renal adenocarcinoma. (1980) (0)
MP79-06 NOVEL GENETIC VARIANTS ASSOCIATED WITH UPGRADING IN A SURGICAL AND AN ACTIVE SURVEILLANCE COHORT (2014) (0)
842: Does Perineural Invasion in the Prostate Biopsy Specimen Matter? (2007) (0)
Bladder tumors invading the lamina propria (stage A/T1): Influence of endovesical bacillus Calmette-Guerin therapy on recurrence and progression: Editorial comment (1990) (0)
DOES PSA VELOCITY ENHANCE THE PREDICTION OF NONORGAN CONFINED DISEASE BEYOND PSA ALONE (2008) (0)
PSA AND THE DETECTION OF PROSTATE CANCER. AUTHOR'S REPLY (1994) (0)
843: PSA Velocity Predicts Gleason Grade in the Radical Prostatectomy Specimen: A Marker for Prostate Cancer Aggressiveness (2007) (0)
715 GENETIC RISK VARIANTS ON 8Q24 ASSOCIATED WITH PROSTATE CANCER AGGRESSIVENESS (2011) (0)
Editorial comment. (2010) (0)
Adverse effect of fibrin clot inhibitors on intravesical BCG therapy for superficial bladder tumors (1990) (0)
Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma or urinary bladder: Cause for concern: Editorial comment (1990) (0)
1334 COMPARISON OF PATHOLOGICAL OUTCOMES FOLLOWING RADICAL PROSTATECTOMY IN CONTEMPORARY EUROPEAN AND NORTH AMERICAN SCREENED POPULATIONS OVER THE LAST TEN YEARS (2012) (0)
Bacillus Calmette-Guerin treatment and vesicorenal reflux: Editorial comment (1990) (0)
MP64-19 ASSOCIATION BETWEEN INFLAMMATORY BOWEL DISEASE AND PROSTATE CANCER WITH COLORECTAL CANCER AS A COMPARATOR: A PROSPECTIVE, POPULATION-BASED STUDY (2020) (0)
1918 DO MEN FLUCTUATE ABOVE AND BELOW THEIR AGE-SPECIFIC MEDIAN PSA VALUES AS THEY AGE? (2012) (0)
Characterization and Partial Purification of a Non-Heparin-Binding Prostate Growth Factor from Cancerous Human Prostate (1991) (0)
Potency-sparing modification of radical retropubic prostatectomy (1987) (0)
732: Percentage and Tumor Features of Patients who Develop Undetectable PSA Levels after Salvage Radiotherapy (2007) (0)
1451 PROSPECTIVE OBSERVATIONAL STUDY OF VENOUS THROMBOEMBOLISM RISK OF PATIENTS UNDERGOING PARTIAL AND RADICAL NEPHRECTOMY (2013) (0)
Early Diagnosis and Aggressive Treatment is the Only Option for Cure of Prostate Cancer (2003) (0)
Combination of tests improves detection of prostate cancer (1993) (0)
297 ARE NEWLY DESCRIBED PROSTATE CANCER SUSCEPTIBILITY VARIANTS ASSOCIATED WITH PROSTATE CANCER AGGRESSIVENESS (2010) (0)
Heightened lnterferon-7 Production by Mononuclear Cells from Bladder Cancer Patients1 (2006) (0)
ASSOCIATION OF PROSTATE CANCER GENETIC RISK ALLELES WITH PROSTATE BIOPSY RESULTS (2009) (0)
1737 MOST PARSIMONIOUS MODEL WITH GENETIC VARIANTS TO EVALUATE PROSTATE CANCER RISK (2010) (0)
1752 PREVENTING THROMBOEMBOLIC COMPLICATIONS AFTER RADICAL RETROPUBIC PROSTATECTOMY WITH COMPRESSION STOCKINGS AND AMBULATION ONLY (2010) (0)
Lymphadenectomy for Carcinoma of the Penis (1989) (0)
NEW STATISTICAL MODEL FOR TIME-DEPENDENT COVARIATES TO QUANTIFY RISK FOR REPEAT PROSTATE BIOPSY (2008) (0)
1651: The Percent Age Increase in PSA as Predictor of Tumor Features in the Radical Prostatectomy Specimen (2006) (0)
Estimation of growth fraction in situ in human bladder cancer with bromodeoxyuridine labelling: Editorial comment (1990) (0)
633: Comparison of Prostate Cancer Prevention Trial Placebo Group with Longitudinal Prostate Cancer Screening Study (2004) (0)
Editorial comment. (2009) (0)
Reply by the Authors. (2017) (0)
1264: Percent Free PSA and PSA Density as Predictors of Progression-Free Survival (2004) (0)
Editorial comment. (2010) (0)
456: MHL-1: New Immunohistochemical Marker for Prostate Cancer (2005) (0)
Intravesical therapy in the management of superficial transitional cell carcinoma of the bladder: The experience of the EORTC GU Group: Editorial comment (1990) (0)
Factors influencing intravesical adherence of bcg and their effect on antitumor activity (1985) (0)
371 ARE GENETIC VARIANTS THAT PROMOTE PSA EXPRESSION ASSOCIATED WITH MORE FAVORABLE PATHOLOGIC TUMOR FEATURES (2012) (0)
Positive surgical margins at radical prostatectomy: Importance of the apical dissection: Editorial comment (II) (1990) (0)
Re: Serum prostate specific antigen as prescreening test for prostate cancer. (1993) (0)
Evidence to support a decline in prostate cancer-specific mortality (2005) (0)
Complications of Nerve-Sparing Radical Retropubic Prostatectomy (1987) (0)
Overview Prostate cancer is the most commonly diagnosed The NCCN Prostate Cancer Early Detection Clinical Practice Guidelines in OncologyTM (2010) (0)
FREQUENCY OF 8q24 PROSTATE CANCER SUSCEPTIBILITY ALLELES ACROSS AGE GROUPS OF MEN WITH PROSTATE CANCER (2008) (0)
657: Pathologic Features and Outcomes After Radical Prostatectomy for Potential Candidates for Active Monitoring (Low-Volume, Gleason 3+3) (2006) (0)
868: Clinical Implications of Different PSA Values Resulting from Different PSA Standards (2006) (0)
Comparing association of preoperative transrectal ultrasound prostate weight with prostate weight obtained after radical prostatectomy after adjustment for other prognostic factors in a subset of the Northwestern University Prostate SPORE database. (2017) (0)
MP16-05 COMPARISON OF PROSTATE HEALTH INDEX (PHI) AND MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING (MRI) IN DETECTION OF CLINICALLY-SIGNIFICANT PROSTATE CANCER (2016) (0)
431: Variants in the Hepsin Gene are Associated with Prostate Cancer in Men of Caucasian Ancestry (2006) (0)
Immunology of Carcinoma of the Prostate: Fact or Fancy (1986) (0)
575 NANOTECHNOLOGY PSA MEASUREMENTS CORRELATE WITH PROSTATE CANCER PATHOLOGY AND RESPONSE TO ADJUVANT TREATMENT (2010) (0)
The influence of decision aids on prostate cancer screening preferences: A randomized survey study. (2018) (0)
1189: Identifying Potentially Life Threatening Prostate Cancer at Diagnosis (2004) (0)
“It just makes sense to me”: Patient experiences with prostate MRI during prostate cancer active surveillance. (2023) (0)
Medicine--more than molecules and money. (1995) (0)
526: Pathologic Stage and Surgical Outcomes of Prostate Cancer with PSA < 4 NG/ML (2006) (0)
Escalated therapy for refractory urothelial tumors: Methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor: Editorial comment (1990) (0)
ARE DIABETES MELLITUS AND CHROMOSOME 17Q12 GENETIC VARIANTS ASSOCIATED WITH PROSTATE CANCER AGGRESSIVENESS (2009) (0)
304 PRELIMINARY EVALUATION OF SENSITIVITY AND SPECIFICITY OF A NANOTECHNOLOGY PSA ASSAY FOR DEFINING PROSTATE CANCER TREATMENT SUCCESS AND FAILURE (2011) (0)
Pelvic Lymph Nodes: Diagnosis and Significance (1987) (0)
Robotic assisted laparoscopic radical prostatectomy versus retropubic radical prostatectomy: A prospective assessment of postoperative pain. Editorial comment (2005) (0)
608: PSA Velocity in Screened Versus Referred Men with Prostate Cancer (2007) (0)
Bone bridging with opposing massive hemicylindrical grafts. (1951) (0)
MP77-08 PROSTATE CANCER PRESENTATION IN A COMMUNITY SETTING A DECADE SINCE THE USPSTF GRADE D RECOMMENDATION (2023) (0)
DIGITAL RECTAL EXAMINATION FOR DETECTING PROSTATE CANCER IN MEN WITH PROSTATE SPECIFIC ANTIGEN LEVELS <4.0 NG./ML. (1999) (0)
REDUCING BLOOD LOSS WITH RADICAL RETROPUBIC PROSTATECTOMY WITH PROPHYLACTIC PERI-PROSTATIC SUTURES (2009) (0)
Renal failure after intravesical mitomycin C: Editorial comment (1990) (0)
MP21-17 BLACK RACE PREDICTS SIGNIFICANT PROSTATE CANCER INDEPENDENT OF CLINICAL SETTING, AND CLINICAL AND SOCIOECONOMIC RISK FACTORS: EVIDENCE FOR A BIOLOGICAL BASIS OF DISPARITIES (2018) (0)
Words of wisdom. Re: Quality-of-life effects of prostate-specific antigen screening. (2013) (0)
969: Long-Term Outcomes of Radical Prostatectomy for Clinically Advanced Prostate Cancer (2006) (0)
1082: Analysis of Candidate SNPs in Prostate Cancer Cases and Disease Free Controls (2004) (0)
287 HOW LONG CAN SURGERY SAFELY BE DELAYED IN MEN WITH LOW-RISK PROSTATE CANCER? (2010) (0)
Re: Prospective evaluation of operating characteristics of prostate cancer detection biomarkers: Y. Liang, D. P. Ankerst, N. S. Ketchum, B. Ercole, G. Shah, J. D. Shaughnessy, Jr., R. J. Leach and I. M. Thompson J Urol 2011; 185: 104-110. (2011) (0)
2224 PROSTATE CANCER RISK ALLELES ARE ASSOCIATED WITH PROSTATE CANCER TUMOR VOLUME BUT NOT PROSTATE SIZE (2012) (0)
V1974: Nerve-Sparing Retropubic Radical Prostatectomy - A Video of the Technique (2004) (0)
“Radical” Partial Nephrectomy for Renal Cell Carcinoma (1987) (0)
Modified groin dissection for carcinoma of the penis with preservation of saphenous veins (1988) (0)
Arthritis associated with adjuvant myobacterial treatment for carcinoma of the bladder: Editorial comment (1990) (0)
1734 IMPROVED PREDICTION OF PROSTATE BIOPSY RESULTS BY COMBINING PROPSA AND GENETIC RISK MARKERS: PROOF-OF-PRINCIPLE STUDY (2010) (0)
Warren D.W. Heston, PhD and Neil H. Bander, MD: Founding Fathers of PSMA Technology. (2022) (0)
7. BCG Therapy for Superficial Bladder Cancer (1984) (0)
Immunotherapy of Urologic Cancer (1982) (0)
PD03-01 YOUNGER AGE IS ASSOCIATED WITH DECREASED RISK OF BIOPSY PROGRESSION DURING ACTIVE SURVEILLANCE FOR LOW AND INTERMEDIATE RISK PROSTATE CANCER (2016) (0)
Re: Association of hemospermia with prostate cancer [1] (multiple letters) (2005) (0)
1913 NANO-PSA IN PATIENTS WITH ADVERSE PATHOLOGICAL FEATURES (2011) (0)
IN MEN WITH RISING PSA AFTER RADICAL PROSTATECTOMY, 8Q24 PROSTATE CANCER RISK ALLELES HELP PREDICT THREATENING CANCER PROGRESSION AND NEED FOR SALVAGE THERAPY (2009) (0)
Editorial comment. (2009) (0)
Conservative management of prostate cancer. (1994) (0)
221: Tumor Characteristics and Treatment Outcomes of Carriers and Noncarriers of the Decode Prostate Cancer Susceptibility Genes (2007) (0)
Clinical Urology: Letters to the EditorRE: USE OF LOWER PROSTATE SPECIFIC ANTIGEN CUTOFFS FOR PROSTATE CANCER SCREENING IN BLACK AND WHITE MEN (1999) (0)
Radical prostatectomy outcomes during prostate-specific antigen era in Ireland compared to a matched American population (2014) (0)
1568 IS PREOPERATIVE 5-ALPHA REDUCTASE INHIBITOR (5ARI) USE ASSOCIATED WITH HIGH-GRADE DISEASE AT RADICAL PROSTATECTOMY? (2010) (0)
622: Does PSA Screening Detect Harmless Cancers? (2004) (0)
PSA screening in men newly diagnosed with colorectal cancer: each according to his group's means? (2013) (0)
1878: Median PSA for the Age Group in Men in their 60S, 70S and 80S (2007) (0)
1059: Adjuvant Radiation Therapy Following Radical Prostatectomy for Adverse Pathology (2004) (0)
The Influence of Serial Prostate-Specific Antigen Screening on the Pre-Diagnostic PSA Velocity Level at Diagnosis (2007) (0)
2032 POSSIBLE PITFALLS IN USING PROSTATE SPECIFIC ANTIGEN VELOCITY FOR DETECTION OF PROSTATE CANCER (2011) (0)
Evidence to Support that Serial Screening Decreases Prostate Cancer-Specific Mortality (2005) (0)
Risk Assessment and DiagnosisReply (2010) (0)
170 20-25% LOWER PSA VALUES WITH PSA TEST STANDARDIZATION TO THE WHO REFERENCE MATERIAL: SUMMARY OF 4 STUDIES IN 1100 PATIENTS (2009) (0)
MP79-03 RESULTS OF THE NCI PROSTATE CANCER GENETICS WORKING GROUP ANALYSIS COMPARING 36 VALIDATED PROSTATE CANCER LOCI WITH AGGRESSIVE DISEASE (2014) (0)
Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21 (2016) (0)
Re: Which Type of Targeted Prostate Biopsy Should We Prefer in Which Patient? (2017) (0)
PSA-based screening for prostate cancer: Where are we now? (2007) (0)
614 RESULTS OF URINE CULTURES AT THE TIME OF CATHETER REMOVAL FOLLOWING RADICAL PROSTATECTOMY (2010) (0)
Diagnosis and treatment of prostate cancer. Beyond the controversy over whether and whom to screen, the appropriate method of screening is also subject to debate. (2008) (0)
20-25% Lower Psa Values With Psa Test Standardization To the Who Reference Material: Summary of 4 Studies in 1100 Patients (2009) (0)
731: Tumor Characteristics of Patients who did and those who did not have Biochemical Progression after Adjuvant or Salvage Postop Radiotherapy (2007) (0)
134: Risk for Prostate Cancer in Men in their 40s who are African-American or have a Positive Family History, if their PSA is Below their Age-Specific Median (2006) (0)
122 NEW RISK ALLELES IN PATIENTS WITH FAMILIAL AND NON-FAMILIAL PROSTATE CANCER (2010) (0)
1336 PCK3145 SUPPRESSES THE INVASIVE CAPABILITIES OF HUMAN PROSTATE CANCER CELLS INDUCED BY TRANSFORMING GROWTH FACTOR BETA (2013) (0)
1421: Follow-Up on Patients with High PSAV and Negative Initial Biopsy (2007) (0)
Urethral involvement in female patients with bladder cancer: A study of 22 cystectomy specimens: Editorial comment (1990) (0)
Methods of early detection (1992) (0)
1916 REGULARITY OF PSA TESTING AND CANCER RECURRENCE IN PROSTATE CANCER PATIENTS (2011) (0)
PD26-06 CHANGES IN PROSTATE HEALTH INDEX (PHI) OVER TIME (2016) (0)
2126 WHAT IS A NORMAL NANOTECHNOLOGY PSA FOLLOWING RADICAL PROSTATECTOMY? (2010) (0)
Determination of mean population values of the prostate-specific antigen test after correcting for verification bias (2005) (0)
Management Aspects of the Genitourinary System (1986) (0)
Screening for prostate cancer (multiple letters) [4] (1997) (0)
1725 GENETIC SEQUENCE VARIANTS ASSOCIATED WITH BOTH SEVERITY OF LOWER URINARY TRACT SYMPTOMS AND PROSTATE CANCER SUSCEPTIBILITY (2012) (0)
New Developments in the Treatment of Localized Prostate Cancer (Chapter 9) (2006) (0)
FIRST-DEGREE FAMILY HISTORY OF PROSTATE CANCER AND CARRIER STATUS OF PROSTATE CANCER RISK ALLELES (2009) (0)
714 OUTCOMES IN PATIENTS WITH GLEASON SCORE 8–10 PROSTATE CANCER: RELATION TO PRE-OPERATIVE PSA LEVEL (2011) (0)
A MULTIPLICATIVE MODEL OF PROSTATE CANCER SUSCEPTIBILITY ALLELES ON 8q24 AND 17q: WHICH COMBINATION IS ASSOCIATED WITH AGGRESSIVE CANCER? (2008) (0)
2049 GENETIC ADJUSTMENT OF PSA VALUES IN AFRICAN-AMERICAN MEN REDUCES POTENTIALLY DELAYED BIOPSIES (2013) (0)
PROSTATE CANCER GENETIC VARIANTS CAN HELP IDENTIFY PATIENTS WITH POSSIBLY “INSIGNIFICANT” PROSTATE CANCER (2009) (0)
PROSTATE CANCER SCREENING MUST BE CONTINUED TO BE EFFECTIVE (2008) (0)
Urology-important advances in clinical medicine: prostatic Acid phosphatase is not a screening test for early prostatic cancer. (1983) (0)
PD38-07 GENETIC CORRECTION OF PSA CAN REDUCE THE NUMBER OF MEN DIAGNOSED WITH POTENTIALLY INSIGNIFICANT PROSTATE CANCER: RESULTS FROM A SURGICAL AND ACTIVE SURVEILLANCE COHORT (2015) (0)
610: Outcomes of Men Managed with Watchful Waiting in the PSA Follow-up Study (2007) (0)
Advances in Urology, Vol. 1. (1988) (0)
1386 THE INFLUENCE OF BODY MASS INDEX ON ERECTILE FUNCTION FOLLOWING RADICAL PROSTATECTOMY (2012) (0)
Highlights from the 20th International Prostate Cancer Update (2010) (0)
Genitourinary Cancer Management of Localized Prostate Cancer (1989) (0)
1748: PSA velocity in men with Prostatitis Documented on the Biopsy Specimen or Prostatectomy Specimen (2007) (0)
1 Title : Post-hoc Analysis for Detecting Individual Rare Variant Risk Associations using Probit Regression Bayesian Variable Selection Methods in Case-Control Sequencing Studies Running Title : Bayesian Probit Rare Variant Analysis (2017) (0)
POST-PROSTATECTOMY ADJUVANT RADIOTHERAPY FOR PATHOLOGICALLY ADVANCED PROSTATE CANCER: IMPACT ON RECURRENCE RATES (1999) (0)
TITLE : Patient Preferences for Outcomes Associated with Surgical Management of Prostate Cancer PRINCIPAL INVESTIGATOR (0)
DOES A LOWER PSA VELOCITY THRESHOLD LEAD TO THE DETECTION OF MORE INSIGNIFICANT CANCERS (2009) (0)
Difficulties in evaluating urinary specimens after local mitomycin therapy of bladder cancer: Editorial comment (1990) (0)
1678: Identifying Patients at Risk for Benign Versus Life Shortening Postoperative Prostate-Specific Antigen Failure (2005) (0)
LOW PERCENT AGREEMENT AND KAPPA COEFICIENT BETWEEN BIOPSY AND PATHOLOGICAL GLEASON SCORES (1999) (0)
472 PROSTATE CANCER RISK ALLELES ARE PRESENT AT SIGNIFICANTLY DIFFERENT FREQUENCIES IN HEALTHY VOLUNTEERS OF DIFFERENT RACES (2012) (0)
WITHDRAWN: History of the discovery and clinical translation of prostate-specific antigen (2014) (0)
Conservative treatment of diffuse carcinoma in situ of the bladder with repeated courses of intravesical therapy: Editorial comment (1990) (0)
Seminar article Open radical retropubic prostatectomy (2007) (0)
Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa: Requirement for the expression of an antitumor response: Editorial comment (1990) (0)
EFFECT OF PREOPERATIVE TURP ON POTENCY AND CONTINENCE RATES AFTER RADICAL RETROPUBIC PROSTATECTOMY (1999) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With William J. Catalona?

William J. Catalona is affiliated with the following schools: